| 000 | 01709 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514163005.0 | ||
| 264 | 0 | _c20040105 | |
| 008 | 200401s 0 0 eng d | ||
| 022 | _a1351-5101 | ||
| 024 | 7 |
_a10.1046/j.1468-1331.2003.00678.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRomi, F | |
| 245 | 0 | 0 |
_aDisease severity and outcome in thymoma myasthenia gravis: a long-term observation study. _h[electronic resource] |
| 260 |
_bEuropean journal of neurology _cNov 2003 |
||
| 300 |
_a701-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 |
_aAutoantibodies _ximmunology |
| 650 | 0 | 4 |
_aAzathioprine _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aConnectin |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle Proteins _ximmunology |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xcomplications |
| 650 | 0 | 4 |
_aProtein Kinases _ximmunology |
| 650 | 0 | 4 |
_aReceptors, Cholinergic _ximmunology |
| 650 | 0 | 4 |
_aRyanodine Receptor Calcium Release Channel _ximmunology |
| 650 | 0 | 4 | _aThymectomy |
| 650 | 0 | 4 |
_aThymoma _xetiology |
| 650 | 0 | 4 |
_aThymus Gland _xpathology |
| 650 | 0 | 4 |
_aThymus Neoplasms _xetiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGilhus, N E | |
| 700 | 1 | _aVarhaug, J E | |
| 700 | 1 | _aMyking, A | |
| 700 | 1 | _aAarli, J A | |
| 773 | 0 |
_tEuropean journal of neurology _gvol. 10 _gno. 6 _gp. 701-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1468-1331.2003.00678.x _zAvailable from publisher's website |
| 999 |
_c14376454 _d14376454 |
||